Skip to main content

Advertisement

Table 5 EORTC QLQ-H&N35 scoring in the morphologically stable head and neck paraganglioma assessed at the onset and end of the assessment

From: Concomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas

Variables Baseline QLQ Post-therapy QLQ P value
Pain 51.8 ± 22.7 26.8 ± 20.8 0.001
Swallowing 31.4 ± 33.3 17.31 ± 16.6 0.786
Senses (taste and smell) 11.1 ± 24.9 10.1 ± 24.3 0.903
Speech 34.5 ± 22.2 30.2 ± 22.2 0.312
Social eating 31.1 ± 33.3 16.6 ± 16.6 0.107
Social contact 29.6 ± 23.7 19.6 ± 19.5 0.175
Sexuality 28.7 ± 25 31.4 ± 16.6 0.705
Teeth 25.9 ± 33.3 16.6 ± 0.1 0.244
Opening mouth 51.2 ± 50 25.6 ± 33.3 0.158
Dry mouth 17.9 ± 17.2 10.25 ± 16 0.251
Sticky saliva 11.1 ± 16 3.7 ± 10.7 0.112
Coughing 38.4 ± 18.4 20.5 ± 21.6 0.002
Felt ill 43.5 ± 33.3 25.6 ± 33.3 0.031
Painkiller 83.3 ± 38.3 18.5 ± 17 < 0.0001
Nutritional supplement 38.4 ± 50.6 5.1 ± 12.1 0.062